
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings has experienced significant growth in its product segments, notably an 11.3% increase in Technology & Data, and a 5.3% global growth in knees, demonstrating robust demand for its innovative solutions. The company's strategic focus on new product development and recent acquisitions has contributed to a healthy balance sheet and performance that aligns or exceeds industry peers. Additionally, Zimmer Biomet has set a favorable FY25 guidance, forecasting reported revenue growth of 6.7% to 7.7%, indicating confidence in sustaining momentum within the orthopedic market.
Bears say
The negative outlook on Zimmer Biomet Holdings's stock is underscored by the company's expectation of flat average selling prices (ASP) for fiscal year 2025, which, combined with modest headwinds from selling day differences, points to stagnation in revenue growth. Furthermore, the company's knee and hip product segments are experiencing growth challenges compared to peers, with weak performance particularly noted in hip sales, leading to downward revisions in operating margin estimates for the upcoming quarters. Finally, ongoing risks, including potential loss of market share, execution difficulties, and disappointing results from new product initiatives, amplify concerns about the firm’s ability to achieve favorable growth and operational performance moving forward.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares